Derma Sciences, Inc. (DSCI) Enters The Skin Substitute Market With Licensing Agreement For Innovative Amniotic Membrane Wound Care Products
1/14/2014 9:42:30 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces it has licensed exclusive rights to two novel human placental-derived tissue products for all dermal indications in the advanced wound care and burn markets from BioD LLC, a privately held company based in Memphis, Tenn. These products will be branded as AmnioMatrix® and launched during the third quarter of 2014, expanding Derma Sciences’ portfolio of advanced wound care (AWC) products into the $500 million skin substitute market. Terms of the license include an upfront cash payment, royalties on product sales and performance-based milestones to be paid in cash and Derma Sciences stock options.
Help employers find you! Check out all the jobs and post your resume.
comments powered by